In a Phase I dose-escalation study of sibrotuzumab in patients with FAP-positive advanced and metastatic solid tumors, the antibody rapidly and selectively accumulated within tumor stroma, confirming FAP-expressing CAFs as the pharmacologic target (NCT02209727). Here, FAP is linked to neoplasm.